Evidence map›Paper›PMID 33800656›Full record

ArticleCancers2021

MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma.

Lisa Kinget, Eduard Roussel, Diether Lambrechts, Bram Boeckx, Loïc Vanginderhuysen, Maarten Albersen, Cristina Rodríguez-Antona, Osvaldo Graña-Castro, Lucía Inglada-Pérez, Annelies Verbiest and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Single-cell and bulk transcriptomic profiling of metabolism-related lncRNAs reveals tumor heterogeneity and prognostic markers in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Lisa KingetDepartment of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-7479-4793
Eduard RousselDepartment of Urology, University Hospitals Leuven, 3000 Leuven, Belgium.
Diether LambrechtsLaboratory of Translational Genetics, Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.
Bram BoeckxLaboratory of Translational Genetics, Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.
Loïc VanginderhuysenDepartment of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium.
Maarten AlbersenDepartment of Urology, University Hospitals Leuven, 3000 Leuven, Belgium.
Cristina Rodríguez-AntonaCentro Nacional de Investigaciones Oncológicas (CNIO), 28040 Madrid, Spain.
Osvaldo Graña-CastroCentro Nacional de Investigaciones Oncológicas (CNIO), 28040 Madrid, Spain.
Lucía Inglada-PérezDepartment of Statistics and Operational Research, Faculty of Medicine, Complutense University, 28040 Madrid, Spain.
Annelies VerbiestDepartment of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID 0000-0001-9024-863X
Jessica Zucman-RossiCentre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, INSERM, Functional Genomics of Solid Tumors Laboratory, Équipe Labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, F-75006 Paris, France.
Gabrielle CouchyCentre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, INSERM, Functional Genomics of Solid Tumors Laboratory, Équipe Labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, F-75006 Paris, France.
Stefano CarusoCentre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, INSERM, Functional Genomics of Solid Tumors Laboratory, Équipe Labellisée Ligue Nationale contre le Cancer, Labex OncoImmunology, F-75006 Paris, France.
Annouschka LaenenDepartment of Biostatistics, KULeuven, 3000 Leuven, Belgium.
Marcella BaldewijnsDepartment of Pathology, University Hospitals Leuven, 3000 Leuven, Belgium.
Benoit BeuselinckDepartment of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium.
KU Leuven · BEInserm · FRSpanish National Cancer Research Centre · ESVIB-KU Leuven Center for Cancer Biology · BEStatistics Belgium · BEUniversidad Complutense de Madrid · ES

Funding

AstraZenecaBristol-Myers SquibbFonds Wetenschappelijk OnderzoekIpsenKom op tegen KankerMerckPfizer Pharmaceuticals
6 · The paper itself

Abstract

Bone metastasis in clear-cell renal cell carcinoma (ccRCC) leads to substantial morbidity through skeletal related adverse events and implicates worse clinical outcomes. MicroRNAs (miRNA) are small non-protein coding RNA molecules with important regulatory functions in cancer development and metastasis. In this retrospective analysis we present dysregulated miRNA in ccRCC, which are associated with bone metastasis. In particular, miR-23a-3p, miR-27a-3p, miR-20a-5p, and miR-335-3p specifically correlated with the earlier appearance of bone metastasis, compared to metastasis in other organs. In contrast, miR-30b-3p and miR-139-3p were correlated with less occurrence of bone metastasis. These miRNAs are potential biomarkers and attractive targets for miRNA inhibitors or mimics, which could lead to novel therapeutic possibilities for bone targeted treatment in metastatic ccRCC.

Indexed as

bone metastasismicroRNAmiR-139-3pmiR-20a-5pmiR-23a-3pmiR-27a-3pmiR-30b-3pmiR-335-3prenal cell carcinomaSATB2

Identifiers

PMID33800656
PMCPMC8036650
OpenAlexW3150651734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.